TTP has a unique peptide stabilization which should provide a number of new therapeutics. After starting with stable liquid glucacon for treating by hypoglycemia by auto-injection, TTP's other therapeutics may include stabilizing insulin and peptides for osteoperosis and weight loss. All such therapeutics have revenue potential of $2 billion each. Company is seeking $300,000 to optimize liquid glucagon.